LA JOLLA LJP 394 IND FILING FOR LUPUS SLATED FOR SECOND HALF OF 1994
LA JOLLA LJP 394 IND FILING FOR LUPUS SLATED FOR SECOND HALF OF 1994, the San Diego biotech company said in a May 24 prospectus for an initial public offering. LJP 394, La Jolla Pharmaceutical's lead compound, is a product of the company's Tolerance Technology, which is designed to treat auto-immune diseases.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth